ARTA
URGN icon

A.R.T. Advisors’s UroGen Pharma URGN Stock Holding History

A.R.T. Advisors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-14,203
Closed -$338K – 1740
2019
Q3 		$338K Buy
14,203
+3,100
+28% +$101K 0.02% 1007
2019
Q2 		$399K Buy
+11,103
New +$409K 0.02% 838
2018
Q3 		– Sell
-5,500
Closed -$273K – 1730
2018
Q2 		$273K Buy
+5,500
New +$320K 0.01% 1141

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

A.R.T. Advisors's URGN Position: Q4 2019 in Review

A.R.T. Advisors sold out of UroGen Pharma (URGN) in Q4 2019, closing a stake of 14,203 shares — an estimated $338K sold.

A.R.T. Advisors first reported a position in URGN in Q2 2018 and held it in 3 quarters. The position peaked at $399K in Q2 2019. 86 funds tracked by Wall St. Rank hold URGN as of Q4 2019.

  • A.R.T. Advisors reported no remaining UroGen Pharma position as of Q4 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 14,203 UroGen Pharma shares in Q4 2019, an estimated $338K.
  • A.R.T. Advisors first reported a position in UroGen Pharma in Q2 2018 and held it in 3 quarters.
  • A.R.T. Advisors's UroGen Pharma position peaked at $399K in Q2 2019.
  • 86 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.